Skip to main content
OpenTrials
Completed

NCT Number: NCT00261222

Efficacy of Amodiaquine in the Treatment of Uncomplicated Falciparum Malaria in Young Children of Burkina Faso

Design: Single-centre

Indication: Malaria caused by Plasmodium falciparum Objectives: To determine and compare the efficacy of AQ treatment in young children with uncomplicated falciparum malaria in the rural and the urban study area of the Centre de Recherche en Santé de Nouna (CRSN).

Population: Children aged 6-59 months with uncomplicated falciparum malaria (axillary temperature ≥ 37.5°C + ≥ 2.000 P. falciparum asexual parasites per µl blood) from the health centre situated in the villages of Bagala, Bourasso and Kemena and from Nouna town hospital outpatient department.

Sample size: N=120

Treatment: All children will receive a total dose of 25 mg/kg oral AQ over a period of three days (first and second day: 10mg/kg, third day: 5mg/kg).

Statistical procedures: The primary analysis parameter is the proportion of clinical failures on day 14. Secondary parameters are the rate of clinical failures on day 28 (with and without PCR correction), the rate of early clinical failures, the rate of late parasitological failures (day 14 and day 28), and the rate of adverse events. Data will be analysed in the overall group of study children and for rural (n=50) and urban (n=50) study children separately.

Study duration and dates: The study will be implemented in September-December 2005.

Completed

Looking for future studies?

Notify Me

Key information

Age range

6 month–59 month

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Centre de Recherche en Santé de Nouna (CRSN)

Nouna, P.O. Box 34, Burkina Faso

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 6-59 months
  • Uncomplicated falciparum malaria (axillary temperature ≥ 37.5°C and ≥ 2.000 P. falciparum asexual parasites per µl blood)
  • Written informed consent given by the parents/caretakers

Exclusion criteria

  • Complicated or severe malaria (repeated vomiting, seizures or other neurological impairment, haemoglobin < 7 g/dl or haematocrit < 21%)
  • Any apparent significant disease (e. g. pneumonia, meningitis, hepatitis, severe diarrhoea, measles, severe malnutrition)
  • Malaria treatment with western drugs and/or antibiotics with anti malarial potency during last 7 days except chloroquine.

Treatment and study plan

Amodiaquine

Drug

Primary outcomes

  1. Total clinical failure rate on day 14.

  2. Clinical failure rate on day 14 in rural study area.

  3. Clinical failure rate on day 14 in urban study area.

Secondary outcomes

  1. Total clinical failure rate on day 28.

  2. Clinical failure rate on day 28 in rural study area.

  3. Clinical failure rate on day 28 in urban study area.

  4. Total early clinical failure rate.

  5. Early clinical failure rate in rural study area.

  6. Early clinical failure rate in urban study area.

  7. Total late parasitological failure rate on day 14 and 28.

  8. Late parasitological failure rate on day 14 and 28 in rural study area.

  9. Late parasitological failure rate on day 14 and 28 in urban study area.

  10. Incidence of observed and self-reported adverse events over the 28 days observation period

  11. Monitoring of concomitant drug intake

Sponsors and collaborators

Lead sponsor

Heidelberg University

Other

Collaborators

  • Centre de Recherche en Sante de Nouna, Burkina Faso

Registry information

Important dates

Study start
2005
Study completion
2005
First posted
Dec 2, 2005
Registry last updated
Feb 3, 2010

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.